ASND vs SNY
Ascendis Pharma A/S vs Sanofi — AI-powered side-by-side comparison
ASND
Ascendis Pharma A/S
66
Buy
VS
SNY
Sanofi
62
Insufficient Data
| Metric | ASND | SNY |
|---|
| AI Score |
66
|
62
|
| Price |
$254.27
|
$43.56
|
| P/E Ratio |
26.92×
|
23.06×
|
| ROE |
134.6%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
88.2%
|
72.8%
|
| Debt / Equity |
1.84×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.5%
|
| RSI (14) |
56.3
|
53.1
|
| Beta |
0.382
|
0.278
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ASND versus SNY.
ASND leads by 4 points.
ASND scores 66/100 (Buy) versus SNY at 62/100 (Insufficient Data).
ASND Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 129.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 134.8% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 27.9 is moderate-to-rich — Value
- Price-to-book of 22.5x prices in significant intangible value — Value
- Debt-to-equity of 1.93 adds balance-sheet risk to the value case — Value
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical